Related references
Note: Only part of the references are listed.Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer harboring uncommon EGFR mutations: Focus on afatinib
Ashiq Masood et al.
SEMINARS IN ONCOLOGY (2019)
The red wine component ellagic acid induces autophagy and exhibits anti-lung cancer activity in vitro and in vivo
Jing Duan et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2019)
Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer
Khyati N. Shah et al.
NATURE MEDICINE (2019)
Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer
Simon Vyse et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2019)
Discovery of a Highly Potent and Broadly Effective Epidermal Growth Factor Receptor and HER2 Exon 20 Insertion Mutant Inhibitor
Jaebong Jang et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2018)
Afatinib and Cetuximab in Four Patients With EGFR Exon 20 Insertion-Positive Advanced NSCLC
Bianca van Veggel et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC
Jonathan W. Riess et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
TAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion Mutations
Shinichi Hasako et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer
Jacqulyne P. Robichaux et al.
NATURE MEDICINE (2018)
A Pharmacological Update of Ellagic Acid
Jose-Luis Rios et al.
PLANTA MEDICA (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Activity of the Hsp90 inhibitor luminespib among non-small-cell lung cancers harboring EGFR exon 20 insertions
Z. Piotrowska et al.
ANNALS OF ONCOLOGY (2018)
Experimental Evidence of the Antitumor, Antimetastatic and Antiangiogenic Activity of Ellagic Acid
Claudia Ceci et al.
NUTRIENTS (2018)
Antitumor activity of tarloxotinib, a hypoxia-activated EGFR TKI, in patient-derived lung cancer cell lines harboring EGFR exon 20 insertions
Adriana Estrada-Bernal et al.
MOLECULAR CANCER THERAPEUTICS (2018)
EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas
Susan E. Jorge et al.
CLINICAL CANCER RESEARCH (2018)
Anti-cancer Effects of Polyphenolic Compounds in Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-resistant Non-small Cell Lung Cancer
Hyungmin Jeong et al.
PHARMACOGNOSY MAGAZINE (2017)
NSCLC harboring EGFR exon-20 insertions after the regulatory C-helix of kinase domain responds poorly to known EGFR inhibitors
Mengmeng Yang et al.
INTERNATIONAL JOURNAL OF CANCER (2016)
Ellagic Acid Inhibits Bladder Cancer Invasiveness and In Vivo Tumor Growth
Claudia Ceci et al.
NUTRIENTS (2016)
Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib
Jarushka Naidoo et al.
CANCER (2015)
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6
James C-H Yang et al.
LANCET ONCOLOGY (2015)
Epidermal growth factor receptor (EGFR) exon 20 mutations in non-small-cell lung cancer and resistance to EGFR-tyrosine kinase inhibitors
Hyun Sun Woo et al.
INVESTIGATIONAL NEW DRUGS (2014)
Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial
Pasi A. Jaenne et al.
LANCET ONCOLOGY (2014)
Natural History and Molecular Characteristics of Lung Cancers Harboring EGFR Exon 20 Insertions
Geoffrey R. Oxnard et al.
JOURNAL OF THORACIC ONCOLOGY (2013)
Combining Erlotinib and Cetuximab Is Associated with Activity in Patients with Non-Small Cell Lung Cancer (Including Squamous Cell Carcinomas) and Wild-Type EGFR or Resistant Mutations
Jennifer J. Wheler et al.
MOLECULAR CANCER THERAPEUTICS (2013)
EGFR Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics
Maria E. Arcila et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Apoptotic markers in a prostate cancer cell line: Effect of ellagic acid
Luca Vanella et al.
ONCOLOGY REPORTS (2013)
Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer
Hiroyuki Yasuda et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Epidermal growth factor receptor (EGFR) mutation and personalized therapy in advanced nonsmall cell lung cancer (NSCLC)
Kunihiko Kobayashi et al.
TARGETED ONCOLOGY (2013)
Comparison of the Efficacy and Safety of EFGR Tyrosine Kinase Inhibitor Monotherapy with Standard Second-line Chemotherapy in Previously Treated Advanced Non-small-cell Lung Cancer: a Systematic Review and Meta-analysis
Wei-Xiang Qi et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION (2012)
Molecular predictors of response to tyrosine kinase inhibitors in patients with Non-Small-Cell Lung Cancer
Samuel Murray et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2012)
EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications
Hiroyuki Yasuda et al.
LANCET ONCOLOGY (2012)
Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship
Julian R. Molina et al.
MAYO CLINIC PROCEEDINGS (2012)
Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer
William Pao et al.
NATURE REVIEWS CANCER (2010)
Foodstuffs for Preventing Cancer: The Preclinical and Clinical Development of Berries
Gary D. Stoner
CANCER PREVENTION RESEARCH (2009)
Black Raspberry Components Inhibit Proliferation, Induce Apoptosis, and Modulate Gene Expression in Rat Esophageal Epithelial Cells
Nancy N. Zikri et al.
NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL (2009)
Cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response
Jenn-Yu Wu et al.
CLINICAL CANCER RESEARCH (2008)
First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations
Lecia V. Sequist et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer
Tetsuya Mitsudomi et al.
CANCER SCIENCE (2007)
Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers
Daniel B. Costa et al.
LUNG CANCER (2007)
Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors
Yuki Yuza et al.
CANCER BIOLOGY & THERAPY (2007)
Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: The Tarceva Lung Cancer Investigation Trial
Ulrich Gatzemeier et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Update on epidermal growth factor receptor mutations in non-small cell lung cancer
Gregory J. Riely et al.
CLINICAL CANCER RESEARCH (2006)
Epidermal growth factor independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression
JR Jiang et al.
CANCER RESEARCH (2005)
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers
H Shigematsu et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Share Paper
